FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2417876721> ?p ?o ?g. }

• W2417876721 abstract "Approximately 10% of B-ALLs harbor CRLF2 rearrangements and have a poor prognosis. Although these leukemias are addicted to JAK2 signaling, ATP-competitive type I JAK2 inhibitors have limited activity (Weigert et al . J Exp Med 2012). This may result from heterodimerization of JAK2 with other JAK family members (Koppikar et al . Nature 2012). Type II inhibitors bind JAK2 in the inactive conformation and may have non-cross resistance with type I inhibitors. In Ba/F3 cells dependent on CRLF2 and the gain-of-function allele JAK2 R683G, the type II JAK2 inhibitor NVP-CHZ868 was more potent (IC50 21nM) than the type I inhibitors NVP-BSK805 (IC50 443nM) and NVP-BVB808 (IC50 111nM). Unlike type I inhibitors, CHZ868 completely abrogated JAK2 and STAT5 phosphorylation. In addition, the JAK2 Y931C allele that confers 4-6-fold resistance to BSK805 and BVB808 did not affect the IC50 of CHZ868. We assessed in vivo efficacy of CHZ868 in mice transplanted with transgenic (CRLF2/JAK2 R683G/Cdkn2a -/- or CRLF2/JAK2 R683G/Pax5 +/- /Ts1Rhr) or primary human CRLF2-rearranged B-ALLs. Mice treated for 5-6 days with CHZ868 (30mg/kg/day PO) had significant reductions in spleen size compared to control mice and complete loss of phospho-STAT5 in residual leukemia cells. In both murine leukemias and human xenografts, CHZ868 prolonged survival compared to controls (p 30) clones sequenced harbored the same JAK2 L884P mutation. Ba/F3 cells expressing CRLF2 with JAK2 R683G/L884P had 14-fold resistance to CHZ868 (R683G IC50 16nM; R683G/L884P IC50 231nM). JAK2 L884P is homologous to an EGFR L747P activating mutation (He et al . Clin Cancer Res 2012), which destabilizes the P-loop and C-helix portion of the kinase domain. Next-generation sequencing of JAK2 from splenocytes of mice that progressed on CHZ868 treatment did not identify L884P or other missense mutations at >1% frequency, suggesting in vivo treatment failure was not due to JAK2 mutation. To improve CHZ868 efficacy, we tested for synergy with multiple chemotherapy agents in MHH-CALL4 cells, which harbor a CRLF2/IGH rearrangement and JAK2 I682F mutation. Among the tested agents, dexamethasone was highly synergistic with CHZ868. In mice transplanted with CRLF2/JAK2 R683G/Pax5 +/- /Ts1Rhr murine B-ALL, a 14-day course of CHZ868 prolonged survival compared to vehicle (p in vitro and in vivo . Thus, combination strategies using dexamethasone with type II JAK2 inhibitors merit testing in patients with relapsed/refractory, JAK2-dependent B-ALL. Citation Format: Loretta S. Li, Nadja Kopp, Shuo-Chieh Wu, Jordy Van Der Zwet, Jacob V. Layer, Oliver Weigert, Amanda L. Christie, Alexandra N. Christodoulou, Huiyun Liu, Akinori Yoda, Thomas Radimerski, David M. Weinstock. Type II JAK2 inhibitor NVP-CHZ868 has potent activity in JAK2-dependent B-cell acute lymphoblastic leukemias (B-ALLs) in vivo. [abstract]. In: Proceedings of the AACR Special Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies; Sep 20-23, 2014; Philadelphia, PA. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(17 Suppl):Abstract nr A23." @default.
• W2417876721 created "2016-06-24" @default.
• W2417876721 creator A5002179064 @default.
• W2417876721 creator A5023711367 @default.
• W2417876721 creator A5026688095 @default.
• W2417876721 creator A5038598397 @default.
• W2417876721 creator A5039983168 @default.
• W2417876721 creator A5043356000 @default.
• W2417876721 creator A5048714300 @default.
• W2417876721 creator A5053674036 @default.
• W2417876721 creator A5054389343 @default.
• W2417876721 creator A5069614210 @default.
• W2417876721 creator A5076774454 @default.
• W2417876721 creator A5079974197 @default.
• W2417876721 date "2015-08-19" @default.
• W2417876721 modified "2023-10-01" @default.
• W2417876721 title "Abstract A23: Type II JAK2 inhibitor NVP-CHZ868 has potent activity in JAK2-dependent B-cell acute lymphoblastic leukemias (B-ALLs) in vivo." @default.
• W2417876721 doi "https://doi.org/10.1158/1557-3265.hemmal14-a23" @default.
• W2417876721 hasPublicationYear "2015" @default.
• W2417876721 type Work @default.
• W2417876721 sameAs 2417876721 @default.
• W2417876721 citedByCount "0" @default.
• W2417876721 crossrefType "proceedings-article" @default.
• W2417876721 hasAuthorship W2417876721A5002179064 @default.
• W2417876721 hasAuthorship W2417876721A5023711367 @default.
• W2417876721 hasAuthorship W2417876721A5026688095 @default.
• W2417876721 hasAuthorship W2417876721A5038598397 @default.
• W2417876721 hasAuthorship W2417876721A5039983168 @default.
• W2417876721 hasAuthorship W2417876721A5043356000 @default.
• W2417876721 hasAuthorship W2417876721A5048714300 @default.
• W2417876721 hasAuthorship W2417876721A5053674036 @default.
• W2417876721 hasAuthorship W2417876721A5054389343 @default.
• W2417876721 hasAuthorship W2417876721A5069614210 @default.
• W2417876721 hasAuthorship W2417876721A5076774454 @default.
• W2417876721 hasAuthorship W2417876721A5079974197 @default.
• W2417876721 hasConcept C153911025 @default.
• W2417876721 hasConcept C207001950 @default.
• W2417876721 hasConcept C2777752497 @default.
• W2417876721 hasConcept C2779391668 @default.
• W2417876721 hasConcept C502942594 @default.
• W2417876721 hasConcept C54355233 @default.
• W2417876721 hasConcept C71924100 @default.
• W2417876721 hasConcept C81885089 @default.
• W2417876721 hasConcept C86803240 @default.
• W2417876721 hasConceptScore W2417876721C153911025 @default.
• W2417876721 hasConceptScore W2417876721C207001950 @default.
• W2417876721 hasConceptScore W2417876721C2777752497 @default.
• W2417876721 hasConceptScore W2417876721C2779391668 @default.
• W2417876721 hasConceptScore W2417876721C502942594 @default.
• W2417876721 hasConceptScore W2417876721C54355233 @default.
• W2417876721 hasConceptScore W2417876721C71924100 @default.
• W2417876721 hasConceptScore W2417876721C81885089 @default.
• W2417876721 hasConceptScore W2417876721C86803240 @default.
• W2417876721 hasLocation W24178767211 @default.
• W2417876721 hasOpenAccess W2417876721 @default.
• W2417876721 hasPrimaryLocation W24178767211 @default.
• W2417876721 hasRelatedWork W1601101287 @default.
• W2417876721 hasRelatedWork W1973985738 @default.
• W2417876721 hasRelatedWork W2053824759 @default.
• W2417876721 hasRelatedWork W2173572713 @default.
• W2417876721 hasRelatedWork W2315022380 @default.
• W2417876721 hasRelatedWork W2341810480 @default.
• W2417876721 hasRelatedWork W2522099393 @default.
• W2417876721 hasRelatedWork W2550269530 @default.
• W2417876721 hasRelatedWork W2554970574 @default.
• W2417876721 hasRelatedWork W2556949782 @default.
• W2417876721 hasRelatedWork W2556952828 @default.
• W2417876721 hasRelatedWork W2559563976 @default.
• W2417876721 hasRelatedWork W2564869076 @default.
• W2417876721 hasRelatedWork W2566220956 @default.
• W2417876721 hasRelatedWork W2576863267 @default.
• W2417876721 hasRelatedWork W2587172576 @default.
• W2417876721 hasRelatedWork W2979662023 @default.
• W2417876721 hasRelatedWork W2979841932 @default.
• W2417876721 hasRelatedWork W2979996329 @default.
• W2417876721 hasRelatedWork W2981008324 @default.
• W2417876721 isParatext "false" @default.
• W2417876721 isRetracted "false" @default.
• W2417876721 magId "2417876721" @default.
• W2417876721 workType "article" @default.